2026 Q2 -tulosraportti
10 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,97%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·52 min sittenI bought more Novo Nordisk shares Thursday and Friday because they are strongly undervalued. And because a fall of minus 10% on better-than-expected financial results with several upgrades, including increasing pill sales, lacks connection to the actual facts. https://seekingalpha.com/article/4935329-the-market-is-still-underestimating-novo-nordisk
Unfortunately, it's not always the case that the company itself is the most important factor for the share value. I myself expect to sell the rest of my holding next week, as I see other places my money can be invested better.
·3 t sittenhttps://www.euroinvestor.dk/nyheder/investor-der-kan-vaere-flere-opjusteringer-i-vente?utm_term=Autofeed&utm_medium=Social&utm_source=Facebook&fbclid=IwVERDUATtE2dwZG9mBWZkaWQWUMguVGgWA6op4d1ybOarriCGiLGRymV4dG4DYWVtAjExAHNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR6wjsCBoSRuFo5OE3-V1B4SoPZlz-xZHjCCMQuVsePi4wMEX2et7TxdWvoKfQ_aem_Cxwa0h-PqvW_rqEugkmPiw#Echobox=1786746631
It is mentally challenging to sit with a loss and wait for a rise. Then the financial report finally comes, with an upward adjustment in addition. And we sink. Then it's probably just a matter of waiting for Q3 in November.
·5 t sittenIf one doesn't believe in a stock, one naturally doesn't have capital in the company. That nothing else has happened than a financial report with disappointing guidance is not true. Novo came with yet another bad piece of news from its pipeline, and the market reacted with a sell-off, and Novo hit price 300 once again. Capital in Novo is currently uninteresting, as Novo has nothing that can move the price in this quarter. CEO has himself said that 2026 will not be a big year. Negative or no growth. And the market doesn't buy shares without growth. And then the story for 2026 is probably no longer. It is a terrible disposition to only have one company in one's portfolio. Novo has become an obsession from 5.30 to 23. A bit less on weekends. Buy ETFs instead. .......I know that some only have this forum as a point of contact, but please try to get some fresh air. Have a good weekend.
5 t sitten
Good session. For me, there is no doubt that Mike Doustdar is the right man in that studio. Doustdar has the ability to deliver relatively honest, simple, and convincing explanations. Furthermore - and you can't buy that for money - he is jovial. Jim Cramer acts like a shy schoolgirl because he likes Mike. Sorry, it got a bit gushy:)- ·6 t sittenWhen the price falls, many people quickly appear, saying that Novo is finished and that one should sell. But ask yourselves: How many of them actually own Novo themselves? I personally believe Novo will rise again. Not necessarily tomorrow or next month, but because the foundation is still strong. Novo has an enormous position within GLP-1, obesity care grew 37 % in Q2, the Wegovy pill is being rolled out in more markets, and new treatments are being further developed in the pipeline. Yes, competition from Lilly is real, and Novo has challenges that need to be solved. But the company is far from finished. Think long-term. Don't sell a strong company cheaply, just because the sentiment is bad right now. The same people who shout "sell!" when the price is under pressure, might be first in line when Novo is again heading towards 400. 📈
I think Novo has been in focus too much, and after the company had its own "bubble" in 2024, where it was hugely "overvalued", investors' expectations have similarly risen, and to such an extent that it is currently just pure fiction and impossible for the company to deliver on. So right now, even though Novo delivers strongly, it's still just "not enough" for investors, even though the numbers are quite good. 🤷♂️ There has just been a huge price correction, but now that the bottom has been reached again, I have no doubt that it will go up for them in the long term. But people just have to accept that 2024 was a huge outlier which probably won't happen again in this way.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
10 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,97%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·52 min sittenI bought more Novo Nordisk shares Thursday and Friday because they are strongly undervalued. And because a fall of minus 10% on better-than-expected financial results with several upgrades, including increasing pill sales, lacks connection to the actual facts. https://seekingalpha.com/article/4935329-the-market-is-still-underestimating-novo-nordiskUnfortunately, it's not always the case that the company itself is the most important factor for the share value. I myself expect to sell the rest of my holding next week, as I see other places my money can be invested better.
- ·3 t sittenhttps://www.euroinvestor.dk/nyheder/investor-der-kan-vaere-flere-opjusteringer-i-vente?utm_term=Autofeed&utm_medium=Social&utm_source=Facebook&fbclid=IwVERDUATtE2dwZG9mBWZkaWQWUMguVGgWA6op4d1ybOarriCGiLGRymV4dG4DYWVtAjExAHNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR6wjsCBoSRuFo5OE3-V1B4SoPZlz-xZHjCCMQuVsePi4wMEX2et7TxdWvoKfQ_aem_Cxwa0h-PqvW_rqEugkmPiw#Echobox=1786746631It is mentally challenging to sit with a loss and wait for a rise. Then the financial report finally comes, with an upward adjustment in addition. And we sink. Then it's probably just a matter of waiting for Q3 in November.
- ·5 t sittenIf one doesn't believe in a stock, one naturally doesn't have capital in the company. That nothing else has happened than a financial report with disappointing guidance is not true. Novo came with yet another bad piece of news from its pipeline, and the market reacted with a sell-off, and Novo hit price 300 once again. Capital in Novo is currently uninteresting, as Novo has nothing that can move the price in this quarter. CEO has himself said that 2026 will not be a big year. Negative or no growth. And the market doesn't buy shares without growth. And then the story for 2026 is probably no longer. It is a terrible disposition to only have one company in one's portfolio. Novo has become an obsession from 5.30 to 23. A bit less on weekends. Buy ETFs instead. .......I know that some only have this forum as a point of contact, but please try to get some fresh air. Have a good weekend.
- 5 t sittenGood session. For me, there is no doubt that Mike Doustdar is the right man in that studio. Doustdar has the ability to deliver relatively honest, simple, and convincing explanations. Furthermore - and you can't buy that for money - he is jovial. Jim Cramer acts like a shy schoolgirl because he likes Mike. Sorry, it got a bit gushy:)
- ·6 t sittenWhen the price falls, many people quickly appear, saying that Novo is finished and that one should sell. But ask yourselves: How many of them actually own Novo themselves? I personally believe Novo will rise again. Not necessarily tomorrow or next month, but because the foundation is still strong. Novo has an enormous position within GLP-1, obesity care grew 37 % in Q2, the Wegovy pill is being rolled out in more markets, and new treatments are being further developed in the pipeline. Yes, competition from Lilly is real, and Novo has challenges that need to be solved. But the company is far from finished. Think long-term. Don't sell a strong company cheaply, just because the sentiment is bad right now. The same people who shout "sell!" when the price is under pressure, might be first in line when Novo is again heading towards 400. 📈I think Novo has been in focus too much, and after the company had its own "bubble" in 2024, where it was hugely "overvalued", investors' expectations have similarly risen, and to such an extent that it is currently just pure fiction and impossible for the company to deliver on. So right now, even though Novo delivers strongly, it's still just "not enough" for investors, even though the numbers are quite good. 🤷♂️ There has just been a huge price correction, but now that the bottom has been reached again, I have no doubt that it will go up for them in the long term. But people just have to accept that 2024 was a huge outlier which probably won't happen again in this way.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
2026 Q2 -tulosraportti
10 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
3,97%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·52 min sittenI bought more Novo Nordisk shares Thursday and Friday because they are strongly undervalued. And because a fall of minus 10% on better-than-expected financial results with several upgrades, including increasing pill sales, lacks connection to the actual facts. https://seekingalpha.com/article/4935329-the-market-is-still-underestimating-novo-nordiskUnfortunately, it's not always the case that the company itself is the most important factor for the share value. I myself expect to sell the rest of my holding next week, as I see other places my money can be invested better.
- ·3 t sittenhttps://www.euroinvestor.dk/nyheder/investor-der-kan-vaere-flere-opjusteringer-i-vente?utm_term=Autofeed&utm_medium=Social&utm_source=Facebook&fbclid=IwVERDUATtE2dwZG9mBWZkaWQWUMguVGgWA6op4d1ybOarriCGiLGRymV4dG4DYWVtAjExAHNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR6wjsCBoSRuFo5OE3-V1B4SoPZlz-xZHjCCMQuVsePi4wMEX2et7TxdWvoKfQ_aem_Cxwa0h-PqvW_rqEugkmPiw#Echobox=1786746631It is mentally challenging to sit with a loss and wait for a rise. Then the financial report finally comes, with an upward adjustment in addition. And we sink. Then it's probably just a matter of waiting for Q3 in November.
- ·5 t sittenIf one doesn't believe in a stock, one naturally doesn't have capital in the company. That nothing else has happened than a financial report with disappointing guidance is not true. Novo came with yet another bad piece of news from its pipeline, and the market reacted with a sell-off, and Novo hit price 300 once again. Capital in Novo is currently uninteresting, as Novo has nothing that can move the price in this quarter. CEO has himself said that 2026 will not be a big year. Negative or no growth. And the market doesn't buy shares without growth. And then the story for 2026 is probably no longer. It is a terrible disposition to only have one company in one's portfolio. Novo has become an obsession from 5.30 to 23. A bit less on weekends. Buy ETFs instead. .......I know that some only have this forum as a point of contact, but please try to get some fresh air. Have a good weekend.
- 5 t sittenGood session. For me, there is no doubt that Mike Doustdar is the right man in that studio. Doustdar has the ability to deliver relatively honest, simple, and convincing explanations. Furthermore - and you can't buy that for money - he is jovial. Jim Cramer acts like a shy schoolgirl because he likes Mike. Sorry, it got a bit gushy:)
- ·6 t sittenWhen the price falls, many people quickly appear, saying that Novo is finished and that one should sell. But ask yourselves: How many of them actually own Novo themselves? I personally believe Novo will rise again. Not necessarily tomorrow or next month, but because the foundation is still strong. Novo has an enormous position within GLP-1, obesity care grew 37 % in Q2, the Wegovy pill is being rolled out in more markets, and new treatments are being further developed in the pipeline. Yes, competition from Lilly is real, and Novo has challenges that need to be solved. But the company is far from finished. Think long-term. Don't sell a strong company cheaply, just because the sentiment is bad right now. The same people who shout "sell!" when the price is under pressure, might be first in line when Novo is again heading towards 400. 📈I think Novo has been in focus too much, and after the company had its own "bubble" in 2024, where it was hugely "overvalued", investors' expectations have similarly risen, and to such an extent that it is currently just pure fiction and impossible for the company to deliver on. So right now, even though Novo delivers strongly, it's still just "not enough" for investors, even though the numbers are quite good. 🤷♂️ There has just been a huge price correction, but now that the bottom has been reached again, I have no doubt that it will go up for them in the long term. But people just have to accept that 2024 was a huge outlier which probably won't happen again in this way.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt